Dexcom offers recurring CGM revenue, high capital returns, and substantial long-term diabetes-monitoring growth potential at a compressed historical valuation, although Abbott competition and reimbursement constraints could limit upside.
Medical Devices
63 tickers in this themeAgilent is a high-quality, cash-generative tollbooth in life sciences and analytical instruments with rapid margin expansion, though investors must accept a steep valuation premium amid cyclical biotech capex headwinds and China trade risk.
Insulet combines recurring Omnipod revenue, strong international growth, and improving profitability with a sharply compressed valuation, although intensifying insulin pump competition and weaker cash conversion threaten future returns.
ResMed combines a durable sleep therapy franchise, recurring mask revenue, and high cash returns with a relatively attractive valuation, although evolving treatment alternatives and operating-margin pressure could constrain future earnings growth.
Align Technology combines Invisalign's durable clinical franchise, strong cash flow, and attractive valuation with earnings recovery potential, although clear aligner price competition and weaker scanner demand could constrain growth.
Globus Medical offers an attractive valuation backed by strong cash flow and a differentiated spine surgery ecosystem, but sustained upside depends on stabilizing Nevro demand and restoring underlying revenue growth.
Teledyne combines durable imaging and defense-electronics franchises with strong cash generation and growing demand, but premium valuation and acquisition integration risks limit its margin of safety.
GE HealthCare combines a durable medical imaging franchise with expanding diagnostics and software earnings at a moderate valuation, although acquisition integration and hospital capital spending cycles could constrain returns.
Intuitive Surgical combines a dominant robotic-surgery ecosystem with recurring procedure revenue and strong cash generation, but its premium valuation and planned instrument-pricing reductions constrain near-term upside.
Alcon offers durable global eye-care demand, improving cash generation and a discounted historical valuation, but U.S. implant competition and weak reported capital efficiency could limit earnings growth.
Stryker combines a durable medical-device franchise, strong cash generation and a historically compressed valuation, but weaker guidance, cybersecurity exposure and acquisition impairments challenge near-term earnings confidence.
Smith & Nephew offers an attractive medical-device recovery opportunity supported by strong sports medicine franchises and improving cash generation, although persistent US orthopedic weakness and reimbursement pressure threaten execution.